يعرض 861 - 880 نتائج من 19,776 نتيجة بحث عن '(( significant increase decrease ) OR ( significantly ((mean decrease) OR (a decrease)) ))', وقت الاستعلام: 0.66s تنقيح النتائج
  1. 861

    The strength of the commute time-functional connectivity relationship demonstrates weak pathological significance and weak dependency on age. حسب Rostam M. Razban (22232522)

    منشور في 2025
    "…The corresponding Kolmogorov-Smirnov pairwise tests are not significant (S5 Table in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0331085#pone.0331085.s001" target="_blank">SI</a>). …"
  2. 862
  3. 863
  4. 864

    BMI curve for LSES. حسب Krystal Hunter (6820052)

    منشور في 2025
    الموضوعات:
  5. 865
  6. 866
  7. 867
  8. 868
  9. 869

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  10. 870

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  11. 871

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  12. 872
  13. 873
  14. 874
  15. 875
  16. 876
  17. 877
  18. 878
  19. 879
  20. 880